Purpose Importance of polymorphisms in NF-B1 and NF-BI genes for melanoma risk, clinicopathological features and tumor progression is analyzed in Swedish melanoma patients. Patients and methods Functional polymorphisms of NF-B1 and NF-BI genes were examined in 185 melanoma patients and 438 tumor-free individuals. Associations of the polymorphisms with melanoma risk, age and pigment phenotypes of the patients and clinicopathological tumor characteristics were analyzed. DNAs were isolated from mononuclear cells of venous blood. Polymorphisms of the genes were genotyped by a PCR-RFLP technique, and transcription level of NF-BI was examined by a quantitative real-time reverse transcription PCR. Results Both ATTG insertion polymorphism of NF-B1 and A to G polymorphism of NF-BI genes were correlated with melanoma risk, especially, in a combination of ATTG 2 /ATTGT 2 and GG. NF-B1 ATTG 2 /ATTG 2 and NF-BI GG genotypes were associated with male gender and age >65 years (at diagnosis). Patients with ATTG 1 / ATTG 1 genotype had thinner tumors and lower Clark levels at diagnosis. Frequency of ATTG 1 /ATTG 1 genotype was higher in patients with melanomas on intermittently sunexposed pattern of the body and NF-BI GG was more frequent in the patients with melanomas at rarely exposed sites. There were no diVerences in the gene transcription level between patients with diVerent NF-BI genotypes. Conclusion NF-B1 and NF-BI genes might be susceptible genes for melanoma risk and functional polymorphisms of these genes might be biological predictors for melanoma progression.
Introduction
Melanoma is the most aggressive cancer in the skin. Incidence of melanoma has dramatically increased during the last few decades (Greenlee et al.2001 ) and prognosis for the later stages of melanomas is usually very poor due to resistance to current therapy (Balch et al. 2001) . The genetic predisposition for melanoma is highly important (Piepkorn 1994; Winnepenninckx et al. 2006 ) although exposure of ultraviolet (UV) radiation from the sunlight is a major environmental risk factor for melanoma (Houghton and Viola 1981) . The molecular mechanism behind melanoma formation and progression is still not clariWed although a large number of candidate genes have been speculated to be involved in initiation, development and progression of melanoma (Chin 2003; Haluska and Housman 1995; Shahbazi et al. 2002) .
In melanoma, upregulation of nuclear factor-kappa B (NF-B) switch from pro-to antiapoptotic functions, and NF-B is constantly activated in metastatic melanoma (Ueda and Richmond 2006) . Further, UV exposure from the sunlight has been shown to activate NF-B independently from the DNA damaging eVect (Simon et al. 1994) . Activity of NF-B has been observed in various cancer types (Richmond 2002) , including multiple myeloma (Feinman et al. 2004) , breast cancer (Biswas et al. 2000) and melanoma (Shattuck-Brandt and Richmond 1997; Yang and Richmond 2001) to contribute to tumor angiogenesis, progression, and metastasis (Amiri and Richmond 2005; Dolcet et al. 2005; Huang et al. 2000a Huang et al. , 2000c . The most common gene with high frequency of mutations, deletions, and expression in melanoma is the melanoma-associated p16
INK4a gene. DeWciency of the p16
INK4a results in overexpression of cyclin D1, leading to enhancement of cell proliferation (Bartkova et al. 1996) . Moreover, since wild type of p16
INK4a inhibits NF-B transcriptional activity by binding to the NF-B subunit p65 the dysfunction of p16
INK4a results in increased activity of NF-B gene (Becker et al. 2005) .
NF-B is a heterodimer in Rel family with Wve members: RelA, RelB, c-Rel, p50/105 (NF-B1) and p52/p100, and the dimeric form of NF-B p50/RelA is the most common form. In normal cells, NF-B is inactivated in the cytoplasm by binding to their inhibitors, I B , or . When the inhibitory proteins are phosphorylated and degraded, NF-B is subsequently released and further translocated into the nucleus, where the gene transcription is initiated (Gilmore 2003) . NF-B is known to coordinate expression of more than 150 genes and contribute to the balance between apoptosis and survival (Richmond 2002) . In the melanocytes and early stages of melanoma, NF-B upregulates the major pro-apoptotic pathways, leading to caspase activation and apoptosis. However, in late stages of melanoma, these pro-apoptotic pathways are inhibited by activation of the NF-B, which results in tumor growth (Baldwin 1996) .
Several polymorphic sites in NF-B and its inhibitor genes have been identiWed (Campbell and Perkins 2006; Glavac et al. 1994) . Recently, a four nucleotides insertion/ deletion, -94ins/delATTG polymorphism located between two putative key promoter regulatory elements was described in the promoter region of NF-B1 gene which is potentially functional polymorphism in NF-B1 associated with human diseases (Karban et al. 2004) , and cancers (Campbell and Perkins 2006; Lin et al. 2006 ). In addition, there are reports concerning polymorphism in NF-BI gene and various cancer types (Kim et al. 2003; Curran et al. 2002) . In the present study, we examined polymorphisms in both NF-B1 and NF-BI genes in Swedish melanoma patients and tumor-free individuals, and further analyzed associations of the polymorphisms with melanoma risk, patient's age at diagnosis, gender, tumor characteristics, and pigment phenotypes.
Patients and methods
This study was approved by the Regional Ethical Committee at Linköping University, Sweden. The study details were given to all melanoma patients participated and written consents were signed by the patients.
Melanoma patients and tumor-free population
One hundred and eighty-Wve melanoma patients (97 males, 88 females) from southeastern region of Sweden were diagnosed in Linköping University Hospital and Kalmar Hospital within the same geographical region, Sweden. Four hundred and thirty-eight age and gender matched tumorfree individuals from the same region were randomly chosen from our DNA bank. All patients were Caucasian with an average age of 54 years old (range 19-80 years) at diagnosis ( Fig. 1) , and 7/185 patients had multiple primary melanomas. Tumor location was registered on a schematic body chart, as previously described, divided into chronically, intermittently and rarely sun-exposed areas according to clothing habits and general sun-exposure pattern (Stierner er al. 1991) . Tumor characteristics as histopathological subtypes, Breslow thickness, and Clark levels were reviewed from patient's surgery and pathology records (Table 1) . Gender and pigment phenotypes were recorded (Table 2) .
DNA isolation
After the interview, each patient donated 5 ml of venous blood in a heparinized tube for genomic DNA extraction. According to the manufacturer's instruction, genomic DNA Age of melanoma patients at diagnosis (years) was extracted from mononuclear cells by a DNA Blood Maxi Kit from Qiagen (Germany). In brief, blood samples were incubated with buVered detergent at room temperature and then with absolute alcohol at 70°C for at least 10 min. The samples were then taken through spin silicon columns. The columns were washed with buVers and then solved in store buVer provided by Qiagen. DNA concentration was measured by a Nanodrop, ND-1000 Spectrophotometer (Wilmington, DE, USA). DNA working solution of 50 ng/ l in Milli-Q water was prepared from the original DNA stocks and kept at 4°C for further analysis.
Genotyping of NF-B1 and NF-BI by PCR-RFLP Polymorphisms in NF-B1 and NF-BI genes were determined by PCR-RFLP. Primers for NF-B1 were 5Ј-TGGG CACAAGTCGTTTATGA-3Ј and 5Ј-CTGGAGCCGGTA GGGAAG-3Ј, amplifying a fragment of 281 or 285bp. Primers for NF-BI were 5Ј-GGCTGAAAGAACATG-GACTTG -3Ј and 5Ј-GTACACCATTTACAGGAGGG-3Ј which amplify a fragment of 424bps. In brief, the PCR was performed in 20 l mixture containing 50 ng DNA, 1 £ PCR buVer (Promega, Madison, WI, USA), 0.5 M each primer (Invitrogen, Scotland), 1.5 mM (NF-B1) or 3.75 mM (NF-BI ) MgCl 2 , 0.5U DNA polymerase (Promega), 0.25 mM dNTP (Invitrogen). The ampliWcation was performed with annealing temperature of 60°C for 30 s for 35 cycles.
The PCR product of NF-B1 was digested with PXM I (8 U/ l) from Biolabs (New England, UK), in a 20 l reaction system (5 l PCR product + 6 l PFlM I + 6.8 l H 2 O + 2 l 10£ buVer + 0.2 l 100xBSA) at 37°C for 18 h. The ATTG insertion allele had two ATTG at its promoter, named as ATTG 2 , which could be cleaved by PXM I into two lengths of 45 and 240 bp, while the wild type (WT) allele has only one ATTG at its promoter, named as ATTG 1, kept intact after PXM I digestion. The PCR product of NF-BI fragment was digested with a restriction enzyme of HaeIII (10 U/ l) from Promega in a 25 l reaction mixture (10 l PCR product + 2 l HaeIII + 13 l 10£ buVer) at 37°C for 18 h. The G allele had a HaeIII restriction site and was cleaved into two lengths of 108 and 316bp, and the A allele kept intact after HaeIII digestion. Both the PCR and restriction products were visualized in 2% agarose gel with 0.2 g/ml ethidium bromide. DNA ladder (100bp) was included in each run to determine sizes of the fragments. PCRs without DNA template added were used as negative controls. Genotypes of NF-B1 polymorphisms were distinguished as WT (ATTG 1 / ATTG 1 ), heterozygote (ATTG 1 /ATTG 2 ) and polymorphic homozygote (ATTG 2 /ATTG 2 ). Genotypes of NF-BI polymorphisms were determined as WT (AA), heterozygote (AG) and polymorphic homozygote (108 and 316bps, GG).
RNA reverse transcription of NF-BI gene
Peripheral blood (2.5 ml) from the selected patients with NF-BI AA, AG or GG genotype was collected into the PAXgene Blood RNA Tube (DB and Qiagen, Germany) and kept at ¡20°C for RNA isolation. Total RNA was extracted from the peripheral blood mononuclear cells by using PAXgene Blood RNA Kit (DB and Qiagen) and Rnase-FreeDNase set (Qiagen) according to the protocol provided by the manufacturer. In brief, Wrst strand cDNA was reversely transcribed from RNA by using 1st Strand cDNA Synthesis Kit for RT-PCR (Roche applied science, Germany). The cDNA was diluted 20 times in Milli-Q water for Quantitative real-time PCR. ). All cDNA samples including the standards were subjected to quantitative real-time PCR in triplicate. The quantity of the standard was plotted against threshold cycle number, at which the Xuorescence increased above background. The expression of the target gene was evaluated by this standard and shown as value relative to expression in the standard curve. The relative NF-BI expression value was corrected by relative value of ACTB from the same DNA samples. Triplicate NF-BI expression values were individually divided by the relative ACTB values and the mean was named as NF-BI /ACTB normalized.
Statistical analysis
Chi-square test was used to estimate diVerences in frequency distributions of genotypes and alleles in NF-B1 and NF-BI genes between melanoma patients and tumor-free individuals, as well as within subgroups of melanoma patients. Multivariate logistic regression analysis was performed to obtain the adjusted odds ratios (OR) for melanoma risk of polymorphisms and their 95% conWdence intervals (CI). Mann-Whitney test was used to estimate diVerences in gene expression levels between subgroups of patients with various genotypes. All P values shown were two-sided and P < 0.05 was judged as statistical signiWcance.
Results
Tumor characteristics in 185 melanoma patients were examined. Histopathological types of melanomas were divided into melanoma in situ, superWcial spreading melanoma, nodular melanoma, lentigo malignant melanoma, and acro-lentiginous melanoma (Table 1) . Breslow thickness was analyzed in three groups (<0.75, 0.75-1.5 and >1.5 mm), and Clark level in two groups (I + II and III + IV). Tumor location was registered as the Wrst tumor diagnosed, according to sun-exposed body areas and sunexposure behavior. Pigment phenotypes of melanoma patients were registered with the eye and hair color as well as skin types (Table 2) .
Promoter nucleotide insertion polymorphism in NF-B1 gene and melanoma risk Polymorphism of four nucleotide insertion (-94insATTG) at promoter region of NF-B1 gene was determined according to the sizes of PCR fragments. NF-B1 ATTG 1 / ATTG 1 genotype was revealed by the presence of a single 281bp fragment, and heterozygote ATTG 1 /ATTG 2 genotype by the presence of 240 and 285bp fragments, and polymorphic homozygote ATTG 2 /ATTG 2 genotype with the presence of 240bp fragment (Fig. 2) . Distribution of the genotypes was found to be signiWcantly diVerent between melanoma patients and tumor-free individuals (P · 0.025). Frequency of ATTG 2 /ATTG 2 genotype was higher in the patients than the controls (36.2 vs. 26.5%, OR = 1.58, 95%CI: 1.09-2.28). Moreover, the frequency of the ATTG 2 /ATTG 2 genotype was higher in male patients as compared with the controls (44.8 vs. 26.8%, P · 0.001, OR = 2.22, 95%CI: 1.36-3.65). However, female patients did not diVer from controls in the frequency of ATTG 2 / ATTG 2 (P = 0.42). Analysis with cut-oV points of 45 and 65 years of age at diagnosis showed that ATTG 2 /ATTG 2 genotype was associated with the patients over 65 years of age compared with the controls (46.9 vs. 29.4%, P · 0.01, OR = 2.13, 95%CI: 1.10-4.10), but not in the younger patients (Table 3) . Promoter nucleotide insertion polymorphism of NF-B1 gene in melanoma patients
In case-case study, when frequency of the polymorphism distribution was compared between male and female patients, ATTG 2 /ATTG 2 was higher in the males than females (44.8 vs. 27.2%, P · 0.01, OR = 2.16, 95%CI: 1.17-4.01). However, we did not Wnd the diVerence between various age groups of patients (<45, 45-65 and >65 years of age, P · 1, data not shown). As shown in Table 4 , frequency of ATTG 1 /ATTG 1 genotype was decreased by increase in tumor thickness (26.9% in category <0.75 mm, 16% in category 0.75-1.5 mm, 9.3% in category >1.5 mm). The frequency of ATTG 1 /ATTG 1 genotype was signiWcantly lower in patients with the tumor thicker than 0.75 mm compared with those with tumors thinner than 0.75 mm (P = 0.025, OR = 0.388, 95% CI 0.167-0.902). Odds ratio was even lower when comparing patients with tumors thicker than 1.5 mm or thinner than 0.75 mm (P = 0.018, OR = 0.277, 95% CI 0.0917-0.837).
Frequency of the ATTG 1 /ATTG 1 genotype was signiWcantly lower in patients with tumors at Clark stages III and IV (10.3 vs. 28%, P = 0.028, OR = 0.30, 95%CI: 0.13-0.68). Moreover, the ATTG 1 /ATTG 1 genotype was signiWcantly associated with melanomas located on intermittently exposed sites compared with those with the tumor located in chronically exposed areas of the bodies (20.8 vs. 7.0%, P = 0.037, OR = 3.51, 95%CI: 1.02-12.13). Further analysis showed that the polymorphisms were more common in patients with tumor located in intermittently exposed locations than other sites in superWcial spreading melanoma (P = 0.008) although there were few cases. There were no statistical diVerences between diVerent histopathological types of melanomas and between the pigment phenotypes (data not shown).
A to G polymorphism in NF-BI gene and melanoma risk
Genotypes of NF-BI were determined according to the sizes of PCR fragments in melanoma patients and tumor-free individuals. As shown in Fig. 3 , NF-BI AA genotype was represented by the presence of a single 424bp band, and heterozygote AG genotype by the presence of 108, 316 and 424bp fragments, and polymorphic homozygote GG genotype with the presence of 108 and 316bp fragments.
Frequencies of the NF-BI genotypes were signiWcantly diVerent between melanoma patients and the controls (P · 0.01). The GG genotype of NF-BI was signiWcantly higher in the patients (45.4 vs. 32.6%, OR = 1.72, 95%CI: 1.21-2.44). Moreover, frequency of the genotype was even higher in female patients (53.4 vs. 32.0%, OR = 2.44, 95% CI: 1.47-4.04, P · 0.001), and in the patients of 45-65 years of age (P · 0.05) compared with the controls. However, there was no diVerence in the male patients (38.5 vs. 33.5% in male controls, P · 1, Table 5 ). Further, we showed that the G allele was markedly higher in melanoma patients (65.1 vs. 57.9%, P · 0.025 OR = 1.36, 95%CI: 1.06-1.75) and in female patients (69.3 vs. 56.8% in female control, P · 0.001, OR = 1.72, 95%CI: 1.19-2.50), but not in male patients (61.5 vs. 59.1% in male control, P · 1, Table 6 ).
When combinations in distributions of NF-B1 and NF-BI polymorphisms were analyzed in the patients and control individuals, the combination of ATTG2/ATTGT2 and GG revealed even more statistical signiWcance (P < 0.001).
A to G polymorphism of NF-BI gene in melanoma patients
There was no diVerence in distributions of A to G polymorphism between male and females patients (53.4 vs. 38.5, OR = 1.83, 95%CI: 1.02-3.29). When distribution of NF-BI A to G polymorphism was analyzed in patients with 5-year intervals, signiWcance was only found in the patients with age above 60 years at diagnosis. In whole group of the patients, as shown in Table 7 , frequency of the NF-BI GG genotype was not diVerent between the patients >60 and <60 years of age (53.2 vs. 39.8%, P = 0.13). However, if the patients were further divided by gender frequency of the GG genotype, it was found signiWcantly higher in the male patients who were over 60 years of age (51.1 vs. 26.5%, P = 0.02 OR = 2.89, 95%CI: 1.23-6.79), but not in the female patients (P = 0.78).
Association of NF-BI polymorphism with tumor characteristics and patients' pigment phenotypes was also analyzed. Frequency of NF-BI GG genotype was signiWcantly diVerent between patients with tumors located at rarely exposed site and tumors in the other sites (69.6 vs. 43.3%, P = 0.02, OR = 3.0, 95% CI: 1.17 ¡7.67).
NF-BI mRNA expression with A to G polymorphism
In order to investigate inXuence of A to G polymorphism in NF-BI on gene expression, quantitative real-time reverse transcription-PCR was used to quantitate NF-BI mRNA in melanoma patients. Twelve randomly chosen samples (1 with AA, 8 with AG and 3 with GG genotype) were examined. The relative expression of NF-BI mRNA with AA, AG and GG genotype was 1.29, 1.39, and 1.40, respectively. The expression of NF-BI at transcription levels was not diVerent in the melanoma patients with these diVerent genotypes.
Discussion
To our knowledge this is the Wrst report concerning association of polymorphisms in NF-B1 and NF-BI genes with melanoma in a Swedish population. In this study, we found that four nucleotide insertion polymorphism -94insATTG at promoter region of NF-B1 gene and A to G polymorphism in 3Ј UTR region of NF-BI predisposed to melanoma risk, which indicated that the individuals with ATTG 2 /ATTG 2 genotype had usually higher levels of NF-B1 transcript and further increase in production of NF-B protein. NF-B signaling pathway plays an important role in formation, progression, angiogenesis and metastasis of melanoma (Amiri and Richmond 2005; Huang et al. 2000b) . Moreover, single nucleotide polymorphism at 3Ј UTR of NF-BI has eVects on the gene expression by enhancing gene expression (Goto et al. 2001 ). However, we didn't Wnd any eVect of this polymorphism on gene expression, suggesting that other genes in linkage with the G allele might be involved increasing melanoma risk. We found that -94insATTG in NF-B1 gene, ATTG 2 / ATTG 2 genotype was a susceptibility factor in the male patients. ATTG 2 /ATTG 2 genotype was correlated with the patients over the age of 65 years suggesting that the polymorphisms of NF-B1 and BI might function diVerently in the individuals with diVerent age at tumor onset and gender. Since NF-B and their inhibitors are regulated by a variety of factors, including hormones, mitogens and cytokines (Richmond 2002) , these factors might be involved in the alternative expression of NF-BI polymorphism in melanoma patients. Both -94insATTG in NF-B and A to G polymorphism of NF-BI gene were related to melanoma risk in patient's gender and tumor onset dependent manner. In addition, NF-BI GG genotype was signiWcantly higher in the female patients, but not in males, suggesting a strong predisposing function of GG genotype only in the female patients. Moreover, this genotype was signiWcantly associated with male patients with late melanoma onset >60 years.
G 1 /ATTG 1 and NF-BI GG genotypes were related to tumor location. The GG genotype was signiWcantly associated with the melanomas at rarely exposed sites, while frequency of ATTG 1 /ATTG 1 genotype was higher in the patients with melanomas at intermittently exposed sites, indicating that diVerent susceptible polymorphisms or genomic changes were associated with sun-exposure pattern of the body.
We found that NF-B polymorphism was related to Breslow vertical thickness in melanoma. The patients with thinner melanomas were usually those with ATTG 1 /ATTG 1 genotype, and patients with thicker melanomas had less frequency of the genotype, suggesting that NF-B1 might be an important gene for tumor progression. Breslow thickness is an important prognostic factor in melanoma and patients with thinner tumor have a longer survival than those with thicker tumors (Mackie et al. 1985) . Further, frequency of ATTG 1 /ATTG 1 genotype was signiWcantly correlated with the patients with early stage of melanoma (Clark I and II). Taken together, we proposed that NF-B1 ATTG 1 /ATTG 1 genotype might serve as a tumor growth indicator, together with Breslow thickness and Clark level to predict the outcome of melanoma patients.
In conclusion, our case-control study supported the hypothesis that polymorphisms in NF-B1 and NF-BI genes act as susceptible genetic markers to predict melanoma risk, especially, in the combination of ATTG 2 /ATT-GT 2 and GG. In melanoma patients, the genotypes of these polymorphisms were correlated with patient's gender, tumor onset and location. NF-B1 ATTG 1 /ATTG 1 genotype might be a biological marker for melanoma progression. 
